Sökning: onr:"swepub:oai:gup.ub.gu.se/267619" > Intravenous thrombo...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05156naa a2200829 4500 | |
001 | oai:gup.ub.gu.se/267619 | |
003 | SwePub | |
008 | 240528s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2676192 URI |
024 | 7 | a https://doi.org/10.1212/wnl.00000000000049822 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Gensicke, H.4 aut |
245 | 1 0 | a Intravenous thrombolysis and platelet count |
264 | c 2018-01-24 | |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2018 |
520 | a ObjectiveTo study the effect of platelet count (PC) on bleeding risk and outcome in stroke patients treated with IV thrombolysis (IVT) and to explore whether withholding IVT in PC < 100 x 10(9)/L is supported.MethodsIn this prospective multicenter, IVT register-based study, we compared PC with symptomatic intracranial hemorrhage (sICH; Second European-Australasian Acute Stroke Study [ECASS II] criteria), poor outcome (modified Rankin Scale score 3-6), and mortality at 3 months. PC was used as a continuous and categorical variable distinguishing thrombocytopenia (<150 x 10(9)/L), thrombocytosis (>450 x 10(9)/L), and normal PC (150-450 x 10(9)/L [reference group]). Moreover, PC < 100 x 10(9)/L was compared to PC 100 x 10(9)/L. Unadjusted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) from the logistic regression models were calculated.ResultsAmong 7,533 IVT-treated stroke patients, 6,830 (90.7%) had normal PC, 595 (7.9%) had thrombocytopenia, and 108 (1.4%) had thrombocytosis. Decreasing PC (every 10 x 10(9)/L) was associated with increasing risk of sICH (ORadjusted 1.03, 95% CI 1.02-1.05) but decreasing risk of poor outcome (ORadjusted 0.99, 95% CI 0.98-0.99) and mortality (ORadjusted 0.98, 95% CI 0.98-0.99). The risk of sICH was higher in patients with thrombocytopenic than in patients with normal PC (ORadjusted 1.73, 95% CI 1.24-2.43). However, the risk of poor outcome (ORadjusted 0.89, 95% CI 0.39-1.97) and mortality (ORadjusted 1.09, 95% CI 0.83-1.44) did not differ significantly. Thrombocytosis was associated with mortality (ORadjusted 2.02, 95% CI 1.21-3.37). Forty-four (0.3%) patients had PC < 100 x 10(9)/L. Their risks of sICH (ORunadjusted 1.56, 95% CI 0.48-5.07), poor outcome (ORadjusted 1.63, 95% CI 0.82-3.24), and mortality (ORadjusted 1.38, 95% CI 0.64-2.98) did not differ significantly from those of patients with PC 100 x 10(9)/L.ConclusionLower PC was associated with increased risk of sICH, while higher PC indicated increased mortality. Our data suggest that PC modifies outcome and complications in individual patients, while withholding IVT in all patients with PC < 100 x 10(9)/L is challenged. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a acute ischemic-stroke | |
653 | a tissue-plasminogen activator | |
653 | a health-care | |
653 | a professionals | |
653 | a clinical-practice | |
653 | a iv thrombolysis | |
653 | a volume | |
653 | a therapy | |
653 | a thrombocytopenia | |
653 | a association | |
653 | a guidelines | |
653 | a Neurosciences & Neurology | |
700 | 1 | a Al Sultan, A. S.4 aut |
700 | 1 | a Strbian, D.4 aut |
700 | 1 | a Hametner, C.4 aut |
700 | 1 | a Zinkstok, S. M.4 aut |
700 | 1 | a Moulin, S.4 aut |
700 | 1 | a Bill, O.4 aut |
700 | 1 | a Zini, A.4 aut |
700 | 1 | a Padjen, V.4 aut |
700 | 1 | a Kagi, G.4 aut |
700 | 1 | a Pezzini, A.4 aut |
700 | 1 | a Seiffge, D. J.4 aut |
700 | 1 | a Traenka, C.4 aut |
700 | 1 | a Raty, S.4 aut |
700 | 1 | a Amiri, H.4 aut |
700 | 1 | a Zonneveld, T. P.4 aut |
700 | 1 | a Lachenmeier, R.4 aut |
700 | 1 | a Polymeris, A.4 aut |
700 | 1 | a Roos, Y. B.4 aut |
700 | 1 | a Gumbinger, C.4 aut |
700 | 1 | a Jovanovic, D. R.4 aut |
700 | 1 | a Curtze, S.4 aut |
700 | 1 | a Sibolt, G.4 aut |
700 | 1 | a Vandelli, L.4 aut |
700 | 1 | a Ringleb, P. A.4 aut |
700 | 1 | a Leys, D.4 aut |
700 | 1 | a Cordonnier, C.4 aut |
700 | 1 | a Michel, P.4 aut |
700 | 1 | a Lyrer, P. A.4 aut |
700 | 1 | a Peters, N.4 aut |
700 | 1 | a Tatlisumak, Turgutu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology4 aut0 (Swepub:gu)xtatlt |
700 | 1 | a Nederkoorn, P. J.4 aut |
700 | 1 | a Engelter, S. T.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi4 org |
773 | 0 | t Neurologyd : Ovid Technologies (Wolters Kluwer Health)g 90:8q 90:8x 0028-3878x 1526-632X |
856 | 4 8 | u https://gup.ub.gu.se/publication/267619 |
856 | 4 8 | u https://doi.org/10.1212/wnl.0000000000004982 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.